Literature DB >> 25710710

New insights into iron regulation and erythropoiesis.

Airie Kim1, Elizabeta Nemeth.   

Abstract

PURPOSE OF REVIEW: Iron homeostasis and erythropoiesis regulate each other to ensure optimal delivery of oxygen and iron to cells and tissues. Defining the mechanisms of this crosstalk is important for understanding the pathogenesis of common conditions associated with disordered iron metabolism and erythropoiesis. RECENT
FINDINGS: Stress erythropoiesis causes suppression of hepcidin to increase iron availability for hemoglobin synthesis. The erythroid hormone erythroferrone (ERFE) was identified as the mediator of this process. ERFE and additional candidates (TWSG1 and GDF15) may also mediate hepcidin suppression in ineffective erythropoiesis. Several mechanisms by which iron regulates erythropoiesis were also recently identified. Iron deficiency suppresses erythropoietin production via the IRP1-HIF2α axis to prevent excessive iron usage by erythropoiesis during systemic iron restriction. Iron restriction also directly impairs erythroid maturation by inhibiting aconitase, and this can be reversed by the administration of the aconitase product isocitrate. Another novel target is GDF11, which is thought to autoinhibit erythroid maturation. GDF11 traps show promising pharmacologic activity in models of both ineffective erythropoiesis and iron-restricted anemia.
SUMMARY: This review summarizes exciting advances in understanding the mechanisms of iron and erythropoietic regulation, and development of novel therapeutic tools for disorders resulting from dysregulation of iron metabolism or erythropoiesis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25710710      PMCID: PMC4509743          DOI: 10.1097/MOH.0000000000000132

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  66 in total

1.  Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.

Authors:  Sara Gardenghi; Pedro Ramos; Maria Franca Marongiu; Luca Melchiori; Laura Breda; Ella Guy; Kristen Muirhead; Niva Rao; Cindy N Roy; Nancy C Andrews; Elizabeta Nemeth; Antonia Follenzi; Xiuli An; Narla Mohandas; Yelena Ginzburg; Eliezer A Rachmilewitz; Patricia J Giardina; Robert W Grady; Stefano Rivella
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

2.  Stimulated erythropoiesis with secondary iron loading leads to a decrease in hepcidin despite an increase in bone morphogenetic protein 6 expression.

Authors:  David M Frazer; Sarah J Wilkins; Deepak Darshan; Alison C Badrick; Gordon D McLaren; Gregory J Anderson
Journal:  Br J Haematol       Date:  2012-03-26       Impact factor: 6.998

3.  Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice.

Authors:  Emilio Ramos; Léon Kautz; Richard Rodriguez; Michael Hansen; Victoria Gabayan; Yelena Ginzburg; Marie-Paule Roth; Elizabeta Nemeth; Tomas Ganz
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

Review 4.  Iron metabolism: interactions with normal and disordered erythropoiesis.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

5.  Iron control of erythroid development by a novel aconitase-associated regulatory pathway.

Authors:  Grant C Bullock; Lorrie L Delehanty; Anne-Laure Talbot; Sara L Gonias; Wing-Hang Tong; Tracey A Rouault; Brian Dewar; Jeffrey M Macdonald; Jason J Chruma; Adam N Goldfarb
Journal:  Blood       Date:  2010-04-20       Impact factor: 22.113

6.  Liver iron concentrations and urinary hepcidin in beta-thalassemia.

Authors:  Raffaella Origa; Renzo Galanello; Tomas Ganz; Nicolina Giagu; Liliana Maccioni; Gavino Faa; Elizabeta Nemeth
Journal:  Haematologica       Date:  2007-05       Impact factor: 9.941

7.  Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy.

Authors:  Francesco S Loffredo; Matthew L Steinhauser; Steven M Jay; Joseph Gannon; James R Pancoast; Pratyusha Yalamanchi; Manisha Sinha; Claudia Dall'Osso; Danika Khong; Jennifer L Shadrach; Christine M Miller; Britta S Singer; Alex Stewart; Nikolaos Psychogios; Robert E Gerszten; Adam J Hartigan; Mi-Jeong Kim; Thomas Serwold; Amy J Wagers; Richard T Lee
Journal:  Cell       Date:  2013-05-09       Impact factor: 41.582

8.  Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells.

Authors:  Toshihiko Tanno; Prashanth Porayette; Orapan Sripichai; Seung-Jae Noh; Colleen Byrnes; Ajoy Bhupatiraju; Y Terry Lee; Julia B Goodnough; Omid Harandi; Tomas Ganz; Robert F Paulson; Jeffery L Miller
Journal:  Blood       Date:  2009-05-04       Impact factor: 22.113

Review 9.  Manipulation of the hepcidin pathway for therapeutic purposes.

Authors:  Eileen Fung; Elizabeta Nemeth
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

10.  Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis.

Authors:  Antonella Roetto; George Papanikolaou; Marianna Politou; Federica Alberti; Domenico Girelli; John Christakis; Dimitris Loukopoulos; Clara Camaschella
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

View more
  57 in total

1.  Neomorphic effects of the neonatal anemia (Nan-Eklf) mutation contribute to deficits throughout development.

Authors:  Antanas Planutis; Li Xue; Cecelia D Trainor; Mohan Dangeti; Kevin Gillinder; Miroslawa Siatecka; Danitza Nebor; Luanne L Peters; Andrew C Perkins; James J Bieker
Journal:  Development       Date:  2017-02-01       Impact factor: 6.868

Review 2.  New strategies to target iron metabolism for the treatment of beta thalassemia.

Authors:  Paraskevi Rea Oikonomidou; Carla Casu; Stefano Rivella
Journal:  Ann N Y Acad Sci       Date:  2016-02-25       Impact factor: 5.691

3.  Jekyll and Hyde: the role of heme oxygenase-1 in erythroid biology.

Authors:  Anupama Narla; Narla Mohandas
Journal:  Haematologica       Date:  2015-05       Impact factor: 9.941

4.  Growth differentiating factor-15 (GDF-15): A potential biomarker and therapeutic target for cancer-associated weight loss.

Authors:  Lorena Lerner; Jeno Gyuris; Richard Nicoletti; James Gifford; Brian Krieger; Aminah Jatoi
Journal:  Oncol Lett       Date:  2016-09-23       Impact factor: 2.967

5.  Red cell membrane disorders: structure meets function.

Authors:  Mary Risinger; Theodosia A Kalfa
Journal:  Blood       Date:  2020-09-10       Impact factor: 22.113

Review 6.  Hepcidin agonists as therapeutic tools.

Authors:  Carla Casu; Elizabeta Nemeth; Stefano Rivella
Journal:  Blood       Date:  2018-03-09       Impact factor: 22.113

Review 7.  Dysregulated myelopoiesis and hematopoietic function following acute physiologic insult.

Authors:  Tyler J Loftus; Alicia M Mohr; Lyle L Moldawer
Journal:  Curr Opin Hematol       Date:  2018-01       Impact factor: 3.284

8.  Extrahepatic deficiency of transferrin receptor 2 is associated with increased erythropoiesis independent of iron overload.

Authors:  Aaron M Wortham; Devorah C Goldman; Juxing Chen; William H Fleming; An-Sheng Zhang; Caroline A Enns
Journal:  J Biol Chem       Date:  2020-02-13       Impact factor: 5.157

Review 9.  [Diagnostics and treatment of preoperative anemia].

Authors:  C Rosenthal; C von Heymann; L Kaufner
Journal:  Anaesthesist       Date:  2019-08       Impact factor: 1.041

Review 10.  HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.

Authors:  Patrick H Maxwell; Kai-Uwe Eckardt
Journal:  Nat Rev Nephrol       Date:  2015-12-14       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.